Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8198560 | 0.86 | CYP3A4 (0.60) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL7905176 | 0.84 | CYP3A4 (0.58) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL23328877 | 0.83 | RAB9A (0.60) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL21873479 | 0.81 | RAB9A (0.54) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3182382 | 0.81 | KDM4E (0.54) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL12180534 | 0.80 | RAB9A (0.59) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL13680749 | 0.80 | ALDH1A1 (0.46) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL18725058 | 0.79 | CYP3A4 (0.53) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL14438067 | 0.77 | CYP3A4 (0.61) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL23367838 | 0.77 | RAB9A (0.56) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378256-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-05 | — | — | US | disclosed |
| EP-3643718-B1 | HETEROCYCLIC COMPOUND AND ITS USE AS POSITIVE ALLOSTERIC MODULATOR OF THE CHOLINERGIC MUSCARINIC M1 RECEPTOR. | TAKEDA PHARMACEUTICALS CO (JP) | 2023-07-26 | — | — | EP | disclosed |
| CN-110709401-B | Heterocyclic compounds | 武田药品工业株式会社 | 2023-06-13 | — | — | CN | disclosed |
| US-11236099-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| US-20220017530-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| US-20210139491-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| EP-3643718-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-04-29 | — | — | EP | disclosed |
| CN-110709401-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-01-17 | — | — | CN | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017530-A1 | HETEROCYCLIC COMPOUND | SLC10A2, ALPI, VIP | CYP3A4 912/4885CYP2E1 936/4885CYP2A6 642/4885 |
| US-12378256-B2 | Heterocyclic compound | SLC10A2, ALPI, VIP | CYP3A4 912/4885CYP2E1 936/4885CYP2A6 642/4885 |
| US-20210139491-A1 | HETEROCYCLIC COMPOUND | SLC10A2, ALPI, VIP | CYP3A4 912/4885CYP2E1 936/4885CYP2A6 642/4885 |
| US-11236099-B2 | Heterocyclic compound | SLC10A2, ALPI, VIP | CYP3A4 912/4885CYP2E1 936/4885CYP2A6 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.